Comments
yourfanat wrote: I am using another tool for Oracle developers - dbForge Studio for Oracle. This IDE has lots of usefull features, among them: oracle designer, code competion and formatter, query builder, debugger, profiler, erxport/import, reports and many others. The latest version supports Oracle 12C. More information here.

2008 West
DIAMOND SPONSOR:
Data Direct
SOA, WOA and Cloud Computing: The New Frontier for Data Services
PLATINUM SPONSORS:
Red Hat
The Opening of Virtualization
GOLD SPONSORS:
Appsense
User Environment Management – The Third Layer of the Desktop
Cordys
Cloud Computing for Business Agility
EMC
CMIS: A Multi-Vendor Proposal for a Service-Based Content Management Interoperability Standard
Freedom OSS
Practical SOA” Max Yankelevich
Intel
Architecting an Enterprise Service Router (ESR) – A Cost-Effective Way to Scale SOA Across the Enterprise
Sensedia
Return on Assests: Bringing Visibility to your SOA Strategy
Symantec
Managing Hybrid Endpoint Environments
VMWare
Game-Changing Technology for Enterprise Clouds and Applications
Click For 2008 West
Event Webcasts

2008 West
PLATINUM SPONSORS:
Appcelerator
Get ‘Rich’ Quick: Rapid Prototyping for RIA with ZERO Server Code
Keynote Systems
Designing for and Managing Performance in the New Frontier of Rich Internet Applications
GOLD SPONSORS:
ICEsoft
How Can AJAX Improve Homeland Security?
Isomorphic
Beyond Widgets: What a RIA Platform Should Offer
Oracle
REAs: Rich Enterprise Applications
Click For 2008 Event Webcasts
SYS-CON.TV
Today's Top SOA Links


GDS International Announces "Industry Leader of the Year" Award at its Fourth Annual European Pharmaceutical Drug Discovery Summit

MILAN, December 4, 2012 /PRNewswire/ --

Last month, 55 of Europe's biggest players from across the pharmaceutical drug discovery sector convened for two-and-a-half days as they attended the most disruptive event of the year - GDS International's fourth Next Generation Pharmaceutical Drug Discovery summit (NGP DD EU), held at the Meliá Milano Hotel, Milan, Italy.

Europe has been an enduring force in the pharmaceutical industry for decades. However, increased competition due in part to globalisation, economic recession and ICT advancements has levelled the playing field for drug discovery. Wise investment and innovative new technologies are subsequently proving key to staying ahead of competitors. With this in mind, GDS International has created an award to recognise exceptional talent within the sector.

Selected as the winners by a panel of 20 senior executives from the R&D functions of global biopharma companies, Paul O'Riordan - CEO of Synexa Life Sciences, and Henning Steinhagen - SVP Head of Global Drug Discovery for Grünenthal, emerged the winners of this year's "Industry Leader of the Year" award for their pioneering new practices within the industry.

Synexa was awarded the title for its industry-leading approach to providing biopharma clients with biomarker expertise, analysis and insight; whilst Grünenthal was selected for its reorganization and strategy implementation for global chemistry outsourcing, and creating a new biology platform directed to immuno-inflammatory research.

Synexa's CEO, Paul O'Riordan, said: "This award is a tremendous acknowledgment of the hard work we have put in over the past 10 years to develop a biomarker services offering that our clients find really useful. To be honoured in this way by the very clients we strive to satisfy is humbling and extremely rewarding. We will use this vote of confidence to continue pushing boundaries in both the science and business of biomarkers."

He continues: "I thought the conference was fantastic. I had some reservations, but the event well exceeded my expectations. The networking opportunities were invaluable - we met exactly the right people and a wide range of potential clients. These people seemed to really appreciate the opportunity to meet us too, which is not always the case at many conferences, and shows how well-selected they were."

A massively successful event, the NG Pharmaceutical Drug Discovery summit continued its trend of attracting the region's most renowned delegates and addressing the most pressing business challenges faced by executives in the industry today. Providing a stimulating contrast to the traditional event format, GDS International's summits encourage discussion at a truly granular level.

The Next NG Pharmaceutical Drug Discovery Europe summit will be held next September 2013. There will be a range of Europe's biggest drug discovery heavyweights joining the conversation, and a cutting-edge programme in place to provide Next Generation solutions to next year's common pain points.

For more information, please visit:http://www.pharmasummiteurope.com

About GDS International

GDS International is one of the most innovative events and media companies worldwide - and a globally renowned producer of business-to-business summits, conferences, online information and advisory group gatherings. Founded in 1993, GDS International specialises in meeting the B2B marketing needs of our clients. Having a strong presence in mature industrial sectors but a finger on the pulse of emerging markets - as well as up-and-coming B2B business verticals - means we are perfectly placed to capitalise on the exciting developments brought about by the advent of a globalised economy. Our value proposition is simple: we deliver tangible business results from world-class events.

http://www.gdsinternational.com

Contact: Kimberley Hogarth
kimberley.hogarth@gdsinternational.com
+44(0)1179-261-420

 

About PR Newswire
Copyright © 2007 PR Newswire. All rights reserved. Republication or redistribution of PRNewswire content is expressly prohibited without the prior written consent of PRNewswire. PRNewswire shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.

Web 2.0 Latest News
One of the key driving factors behind the various web/mobile performance initiatives is the fact that end-users’ tolerance for latency has nose-dived. Several studies have been published whereby it has been demonstrated that poor performance routinely impacts the bottom line, viz,. # u...
HudsonAlpha Institute for Biotechnology leverages modern IT infrastructure and big-data analytics to power a pioneering research project incubator and genomic medicine innovator.
In the business world, it’s hard to throw a rock without hitting a compliance requirement. All must be obeyed, but some call for a high level of control and auditability. Governing bodies are exerting their authority like never before, increasing the number of auditors and handing out ...
A recent CIO editorial by Bernard Golden regarding the future of private cloud spurred some interesting commentary in my network. The pushback seemed to focus around the viability of the term “private cloud”. These individuals are well-respected thought-leaders in cloud with significan...
One of the many questions that companies face when introducing new enterprise systems either to provide new functionality or incorporate legacy systems from a merger or acquisition is "How do we identify and manage access rights?" Not only do new access approval processes need to be e...
Subscribe to the World's Most Powerful Newsletters
Subscribe to Our Rss Feeds & Get Your SYS-CON News Live!
Click to Add our RSS Feeds to the Service of Your Choice:
Google Reader or Homepage Add to My Yahoo! Subscribe with Bloglines Subscribe in NewsGator Online
myFeedster Add to My AOL Subscribe in Rojo Add 'Hugg' to Newsburst from CNET News.com Kinja Digest View Additional SYS-CON Feeds
Publish Your Article! Please send it to editorial(at)sys-con.com!

Advertise on this site! Contact advertising(at)sys-con.com! 201 802-3021




SYS-CON Featured Whitepapers
ADS BY GOOGLE